Literature DB >> 28708951

Control of a community outbreak of hepatitis A in an area of low endemicity, Wales, 2016.

J Vaz1, C Floyd2, B Mason3, A G Shankar4, H Lewis5.   

Abstract

Incidence of hepatitis A in Wales is low (average of 0.48/100,000 inhabitants from 2004-2015). We describe a community outbreak of hepatitis A involving 3 schools (primary and secondary) in South Wales between March and June 2016 and reflect on the adequacy of the control measures used. Anyone in South Wales epidemiologically linked to a serological and/or RNA positive confirmed case of hepatitis A during the 15-50 d before onset of symptoms (diarrhea, vomiting, fever, nausea, AND jaundice, or jaundice-associated symptom) was defined as a case. Case identification was based on laboratory or GP suspicion notification, changing to active surveillance toward the end. As per national guidance, household contacts were identified and offered immunisation while in schools vaccination followed evidence of transmission. We went beyond guidance by vaccinating street play mates and in secondary schools. Mass vaccination uptake was calculated. There were 17 cases, mostly in children under 16 y of age. All cases had an epidemiological link to either a school or a household case (except primary) and no travel history. Street playing was the only epidemiological link between 2 cases in different schools. A total of 139 household contacts were identified. All schools, including secondary one, had a transmission event preceding mass vaccination (overall uptake 85%, reaching 1,574 individuals) and no tertiary cases emerged after the campaigns. We recommend extending guidance to include actions taken that helped curb this outbreak: 1) vaccinating in secondary school and 2) broadening the household contact definition. Based on our learning we further suggest 3) vaccinating upon identification of a single case who attended school while infectious regardless of source and 4) active case finding by serologically testing contacts.

Entities:  

Keywords:  Hepatitis A; Wales; immunisation; outbreak; schools

Mesh:

Substances:

Year:  2017        PMID: 28708951      PMCID: PMC5647946          DOI: 10.1080/21645515.2017.1347242

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  5 in total

1.  Hepatitis A surveillance in England--how many cases are not reported and does it really matter?

Authors:  N Matin; A Grant; J Granerod; N Crowcroft
Journal:  Epidemiol Infect       Date:  2006-05-10       Impact factor: 2.451

2.  WHO position paper on hepatitis A vaccines: June 2012-recommendations.

Authors: 
Journal:  Vaccine       Date:  2012-11-08       Impact factor: 3.641

3.  Large and prolonged food-borne multistate hepatitis A outbreak in Europe associated with consumption of frozen berries, 2013 to 2014.

Authors:  E Severi; L Verhoef; L Thornton; B R Guzman-Herrador; M Faber; L Sundqvist; R Rimhanen-Finne; A M Roque-Afonso; S L Ngui; F Allerberger; A Baumann-Popczyk; L Muller; K Parmakova; V Alfonsi; L Tavoschi; H Vennema; M Fitzgerald; M Myrmel; M Gertler; J Ederth; M Kontio; C Vanbockstael; S Mandal; M Sadkowska-Todys; M E Tosti; B Schimmer; J O Gorman; K Stene-Johansen; J J Wenzel; G Jones; K Balogun; A R Ciccaglione; L O' Connor; L Vold; J Takkinen; C Rizzo
Journal:  Euro Surveill       Date:  2015-07-23

4.  Exploration of cost effectiveness of active vaccination in the control of a school outbreak of hepatitis A in a deprived community in the United Kingdom.

Authors:  D C Taylor-Robinson; M Regan; N Crowcroft; J V Parry; E Dardamissis
Journal:  Euro Surveill       Date:  2007-12-01

5.  Changing hepatitis A epidemiology in the European Union: new challenges and opportunities.

Authors:  C M Gossner; E Severi; N Danielsson; Y Hutin; D Coulombier
Journal:  Euro Surveill       Date:  2015-04-23
  5 in total
  1 in total

1.  Sequencing of the VP1-2A Genome Segment for Hepatitis A Subtyping.

Authors:  A A Zalesskikh; T N Bystrova
Journal:  Sovrem Tekhnologii Med       Date:  2020
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.